P
Paques Biomaterials
Energy · Balk, Netherlands · Founded 2021
Producing a biodegradable plastic from waste(water) streams MoreLess
Paques Biomaterials has developed a technology that utilizes microbes to produce Polyhydroxyalkanoates (PHA), a biopolymer that is both biobased and biodegradable, from organic waste streams. The company is currently scaling up its production capabilities, with a pilot plant already in operation and a full-scale production facility in development in collaboration with ESKA.
The company's primary product, Caleyda®, is a PHA-based bioplastic that serves as a sustainable alternative to traditional fossil-fuel-based plastics. This material has a wide range of applications, including in composites, 3D printing, adhesives, films, and various coatings. Paques Biomaterials' business model is centered on the production and sale of Caleyda® to businesses seeking to reduce their environmental impact and transition to more circular material sourcing.
The company's target market includes industries that are heavy users of plastics and are under pressure to adopt more sustainable practices. By converting waste into a valuable resource, Paques Biomaterials is positioning itself as a key player in the circular economy.
Keywords: bioplastics, biodegradable materials, PHA, circular economy, waste valorization, sustainable materials, industrial biotechnology, water treatment, green chemistry, polymer science
Company overview
Paques Biomaterials company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2021
- Headquarters
- Balk, Netherlands
- Employees
- 32
- Open positions
- 1
- Dealroom signal
- 86.8
Valuation & funding
Paques Biomaterials funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Jan 2024 | $15M | $62M | Invest-NL · NOM - Northern Netherlands Regional Development Agency | ↗ |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 32 |
| 2025 | 25 |
| 2024 | 19 |
| 2023 | 4 |
| 2022 | 4 |
Growth signals
Paques Biomaterials website traffic
Latest recorded traffic for Paques Biomaterials is 200 monthly website visits, down 88.2% over the last three months. Paques Biomaterials's team grew 28% over the past year.
Hiring
Open positions at Paques Biomaterials
Current openings linked to this company in Dealroom.
Comparisons
Paques Biomaterials compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Paques Biomaterials's talent
Source: Dealroom Talent Intelligence.
Investors
2 investors on Paques Biomaterials's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Paques Biomaterials has talent and traffic
team presence
In the news
Latest news about Paques Biomaterials
Recent press, funding announcements, and product moves mentioning Paques Biomaterials — open to read from the original sources.
Market sentiment
What the market is saying about Paques Biomaterials
An AI-synthesized read of the highest-engagement posts about Paques Biomaterials on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Paques Biomaterials’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.